.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC08_Canakinumab.Canakinumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC08_Canakinumab.Canakinumab| name: | Canakinumab | |
| ATC code: | L04AC08 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 150 | mg |
| volume of distribution: | 6.0 | L |
| clearance: | 0.174 | L/day |
| other parameters in model implementation | ||
Canakinumab is a human monoclonal antibody targeting interleukin-1 beta (IL-1β), used in the treatment of autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (sJIA), and Still's disease. It is an approved immunosuppressive agent, primarily administered to reduce inflammation.
Population pharmacokinetics in adult and pediatric patients with autoinflammatory conditions. Data from observed clinical trials including healthy volunteers and patients with CAPS.
Chakraborty, A, et al., & Roy, S (2012). Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clinical pharmacokinetics 51(6) e1–e18. DOI:10.2165/11599820-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22550964
Chakraborty, A, et al., & Howard, D (2013). Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. Journal of clinical pharmacology 53(12) 1240–1251. DOI:10.1002/jcph.162 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24122883